NUVALENT
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
NUVALENT
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.nuvalent.com
Total Employee:
11+
Status:
Active
Total Funding:
185 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Boundless Bio
Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cellares
Cellares is a life sciences technology company that develops the Cell Shuttle to automate cell therapy manufacturing.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Legendairy Foods
Formo is a cell-ag company that develops animal-free dairy products using nature-identical milk proteins from precision fermentation.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
nQ Medical
nQ Medical is a neurotechnology company allowing Data Defined Disease Management via digital biomarkers using AI.
OnKure Therapeutics
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs.
RootPath Genomics
RootPath Genomics is a biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
SeylanMED
SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis.
Sigilon Therapeutics
Sigilon is a biotech company which specializes in creating immune privileged products for unmet clinical needs.
Totient
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures.
Tyra Biosciences
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Board_member
Board_member
2017-01-01
Current Employees Featured
James Porter CEO @ Nuvalent
CEO
2018-01-01
Alex Balcom Chief Financial Officer @ Nuvalent
Chief Financial Officer
2021-01-01
Christopher D. Turner CMO @ Nuvalent
CMO
2021-03-01
Founder
Stock Details
Investors List
Wellington Management
Wellington Management investment in Series B - Nuvalent
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series B - Nuvalent
Boxer Capital
Boxer Capital investment in Series B - Nuvalent
Viking Global Investors
Viking Global Investors investment in Series B - Nuvalent
Avoro Capital Advisors
Avoro Capital Advisors investment in Series B - Nuvalent
Deerfield
Deerfield investment in Series B - Nuvalent
Driehaus Capital Management
Driehaus Capital Management investment in Series B - Nuvalent
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Nuvalent
Fairmount Funds Management
Fairmount Funds Management investment in Series B - Nuvalent
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series B - Nuvalent
Official Site Inspections
http://www.nuvalent.com Semrush global rank: 5.07 M Semrush visits lastest month: 1.62 K
- Host name: 121.145.67.34.bc.googleusercontent.com
- IP address: 34.67.145.121
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Nuvalent"
Nuvalent | Precisely targeted therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.See details»
Nuvalent Investors - Overview
Nov 12, 2024 · Nuvalent is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer. Leveraging deep expertise in structure-based design, …See details»
Nuvalent - Crunchbase Company Profile & Funding
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite …See details»
Nuvalent Announces "OnTarget 2026" Operating Plan
Jan 8, 2024 · Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to …See details»
Nuvalent, Inc. - LinkedIn
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets.See details»
Nuvalent - The Org
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets.See details»
Nuvalent Highlights Corporate and Pipeline Achievements and …
Nov 14, 2023 · About Nuvalent Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with …See details»
Nuvalent Announces "OnTarget 2026" Operating Plan and Key …
Jan 8, 2024 · Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, …See details»
Nuvalent Announces "OnTarget 2026" Operating Plan and Key …
Jan 8, 2024 · Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer. Well-capitalized to support OnTarget …See details»
Careers - Nuvalent
Want to stay up to date on the latest happenings at Nuvalent, be alerted to new career opportunities, and learn about the newest members of our #NuCrew? Follow us on our social media channels! We are passionate about using our …See details»
Approach - Nuvalent
Nuvalent combines deep expertise in structure-based design with clinical insights from physician-scientists to precisely inhibit clinically proven kinase targets and solve for the dual challenges of kinase resistance and selectivity.See details»
Nuvalent Announces "OnTarget 2026" Operating Plan and Key
Jan 8, 2024 · Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to …See details»
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for …
Feb 27, 2024 · Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, …See details»
Nuvalent Completes $135 Million Series B Financing to Advance …
CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today …See details»
Nuvalent Reports Pipeline and Business Progress and Fourth …
Mar 29, 2022 · Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery …See details»
Nuvalent (NUVL) Earnings Date and Reports 2024 - MarketBeat
6 days ago · Nuvalent announced Q3 2024 earnings on November 12, 2024, reporting an EPS of -$1.28, which missed analysts' consensus estimates of -$0.93 by $0.35. With a trailing EPS of …See details»
Team - Nuvalent
Nuvalent has assembled a world-class team with deep expertise in structure-based drug discovery and oncology drug development.See details»
Nuvalent Investors
Nov 12, 2024 · Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, …See details»
Nuvalent Announces Business and Program Highlights and …
Sep 8, 2021 · Nuvalent, Inc. (Nasdaq: NUVL) is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to …See details»
Pipeline - Nuvalent
Nuvalent is advancing a robust pipeline of novel drug candidates emphasizing kinase selectivity, with parallel lead programs for ROS1 and ALK NSCLC.See details»